Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · UroGen Pharma Ltd. (URGN)

UroGen Pharma signs option and research license with IntraGel, invests up to $7 million

Neutral Impact 3 of 5 product/contract Written later

UroGen Pharma's U.S. subsidiary obtained an exclusive option to license IntraGel Therapeutics' TumoCure product and hydrogel delivery platform for advanced head and neck cancer, plus options on additional products and a research license. The company also agreed to invest up to $7,000,000 in IntraGel's equity securities. The filing does not state financial terms of the option exercise or the size of any future payments.

Key points

  • Agreements dated August 18, 2026 with IntraGel Therapeutics, Ltd., an Israeli company
  • Exclusive option to obtain worldwide license to TumoCure with SRGel platform for advanced head and neck cancer
  • Agreed to invest up to $7,000,000 in IntraGel equity under a Securities Purchase Agreement

The filing

CompanyUroGen Pharma Ltd. (URGN)
Form8-K, current report
Filed with the SECAug 20, 2026, 7:04 AM ET
Accession number0001437749-26-028590

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.